Fulvestrant, a pure estrogen receptor (ER) antagonist, is used as treatment for advanced and 2 metastatic ER-positive breast cancer. Its method of action is unique in that it not only 3 competitively binds to the ER, but also reduces its expression (1) . In preclinical studies, 4 fulvestrant was shown to completely down-regulate tumor ER expression and inhibit 5 estrogen-mediated tumor growth (2). In early clinical studies, no dose-limiting toxicities were 6 detected, and 250 mg intramuscularly every 4 weeks was approved as standard dose, given 7 that higher doses cannot be administered as a single injection due to the solubility of the drug 8 (3, 4). However, serial biopsy studies showed that ER expression is down regulated 9 incompletely at the 250 mg dose (4). A loading-dose regimen was therefore explored more 10 recently: 500 mg at day 1 and 250 mg at day 14, 28 and every 4 weeks thereafter, and a high-11 dose regimen consisting of 500 mg at day 1, 14, 28 and every 4 weeks thereafter. Due to a 12 progression-free survival (PFS) gain in the high-dose regimen from 5.5 to 6.5 months in a 13 phase III trial, the high-dose regimen ultimately became the current standard (5). High-dose 14 fulvestrant as first line metastatic treatment also showed favorable outcome compared with 15 anastrozole, with a median PFS of 23 versus 13 months (6) . However, 38% of patients still do 16 not obtain clinical benefit from fulvestrant and hence progress within 24 weeks of therapy (5).
17
Reasons for therapy failure include lost ER expression and insufficient dosing of fulvestrant 18 (7, 8) . 19 Positron emission tomography/computed tomography (PET/CT) with the tracer fulvestrant, and only one follow-up scan was performed at various pharmacokinetic time 1 points.
2
Our prospective study was designed to evaluate whether the current standard dose of 3 500 mg fulvestrant optimally abolishes ER availability in the tumor at two time points during 4 treatment (day 28 and day 84), where the PET scans were scheduled just prior to the 5 subsequent dose of fulvestrant. Between June 2011 and February 2013, 16 patients were included and assigned to 10 fulvestrant treatment 500 mg intramuscularly on day 1, 14, 28 and every 4 weeks thereafter.
11
All patients had received prior palliative tamoxifen and aromatase inhibitor therapy, and five 12 had received prior palliative chemotherapy. Response to treatment was evaluated by serial 13 CT scan and clinical assessment. Seven patients met the criteria for measurable disease 14 according to response evaluation criteria in solid tumors (RECIST v1.1) at baseline (11), six 15 patients had non-measurable nodal or visceral involvement and three patients had bone-only 16 disease. Detailed patient characteristics at study entry are provided in Table 1 .
17
According to RECIST 1.1 criteria, fulvestrant induced one partial response (PR).
18
Stable disease (SD) was observed in eight patients ≥ 24 weeks; three of these had measurable 19 disease at baseline. In the remaining five patients with SD, no evidence of radiologic or 20 clinical progressive disease (PD) was detected, and all five had a decrease in tumor marker 21 CA15.3 (range; -5% to -66%). Finally, four patients had radiologic PD, and two had clinical The median follow-up was 6.5 months (range 1.9 to 15.9 months). Of the 16 patients, 1 15 discontinued fulvestrant with a median PFS of 6.2 months. The remaining patient had 2 received fulvestrant for more than 16 months. Fulvestrant was well tolerated by nearly all 3 patients. One grade 3 adverse event was observed, a urinary tract infection, after which the 4 patient requested treatment withdrawal despite partial response on the CT scan. lung metastases, one ovarian metastasis and one perineal metastasis). In addition, the CT scan 11 revealed FES-negative metastases (n = 11 bone lesions and one lymph node) in five (31%) of 12 16 patients. Finally, seven liver metastases were detected. FES uptake could not be reliably 13 measured in liver metastases due to high background FES uptake in healthy liver tissue.
14
Baseline maximum standardized uptake value (SUV max ) of FES varied greatly among lesions 15 (median 3.4; range 1.4 to 17.4) and patients (median 2.9; 1.7 to 6.5).
16
A second scan was available for all patients; 12 patients received the second scan at 17 day 28, two patients at day 56 (prior to 4 th fulvestrant administration), and two patients at day 18 84 (prior to 5 th fulvestrant administration). A third scan was available for nine patients, but 19 seven patients did not receive the third scan due to due to early progression (n = 3), treatment 20 withdrawal (n = 2) and logistic reasons (n = 2).
21
At the second scan, the median change in FES uptake for the 16 patients was -85% (- Interestingly, even in the nine patients with ≥ 75% decrease in FES uptake, four 3 patients had residual FES uptake (SUV max ) above 1.5. In the nine patients for whom three 4 scans were available (in 8 of 9 patients on the predefined time points), residual tumor FES 5 uptake did not decrease between Scan 2 and Scan 3 (median SUV max 1.6 v 1.7, P = 0.23), 6 which suggests that the maximum effect of fulvestrant 500 mg can be measured after only characteristics before and during therapy are provided in Table 2 .
10
Heterogeneity in the reduction in FES uptake was seen between lesions within 11 individual patients. For example, one individual had six lesions with  90% reduction in FES 12 uptake with a residual SUV max ≤ 1.5, while in seven other lesions a modest reduction of 50-
13
70% was observed, with residual SUV max as high as 4.9 (Fig. 2) . Based on our predefined 
Correlation between Treatment Outcome and FES-PET Results

22
Baseline tumor FES uptake in metastases of patients having clinical benefit from 23 fulvestrant was similar to that in patients with PD (median SUV max , 3.1 v 2.5, P = 0.6). In our 24 study, a previously published (12, 13) threshold of baseline SUV max ≥ 2.0 did not help to However, the magnitude of changes in tumor FES uptake corrected for physiological 7 background (SUV cor ) was significantly larger in patients having clinical benefit from 8 fulvestrant compared to patients with PD (median change SUV cor , -88% v -58%, P = 0.025).
9
Of nine patients with ≥ 75% change in median FES uptake, 8 (89%) had clinical benefit from 10 fulvestrant therapy, compared to only one of six with < 75% decrease. In addition, median 11 PFS was 3.3 months for patients with < 75% decrease in FES uptake v 11.7 months for 12 patients with ≥ 75% decrease (P < 0.05). FES-uptake at baseline and during treatment for all 13 individual patients and its relation with response is depicted in Fig. 3 . The relative decrease in 14 FES uptake and its relationship with response are shown in Fig. 4 . ROC analysis was 15 performed to evaluate whether a threshold other than the predefined 75% would increase the 16 predictive value. ROC analysis showed that the optimal cutoff point (-76%) was close to our 17 pre-defined threshold of -75%. In a lesion-based analysis, no association between changes in 18 FES uptake in the tumor and size changes on CT scan was detected for the small number of 19 measurable lesions (n = 13).
21
Correlation between Tumor FES Uptake and Plasma Fulvestrant Levels 22 To evaluate whether changes in tumor FES uptake correspond to individual patient 23 plasma fulvestrant levels, blood was drawn on the same day as the PET scan. Plasma 24 fulvestrant levels were determined by liquid chromatography tandem mass spectrometry. 
Tamoxifen Effect on Baseline PET Measures
11
Although it was not pre-specified as a study endpoint, we did observe an impact of Coincidentally, an earlier FES-PET that was performed during treatment with an aromatase 17 inhibitor was available for two of these four patients (14).
18
One patient had clinical benefit despite a reduction in FES uptake of only 32%. In this If patients with residual tamoxifen effects were excluded from our analysis, 7 fulvestrant would have decreased median FES uptake in all patients by 86%, by 91% in 8 patients with clinical benefit (n = 7 patients), and -58% in non-responding patients (n = 4 9 patients). Four of 12 patients (33%) would have had incomplete reduction in ER availability.
10
Seven of eight patients (88%) with >75% decrease in FES uptake would have had clinical 11 benefit from fulvestrant therapy, compared to none of four patients with incomplete reduction 12 in FES-uptake. When data adjusted for previous tamoxifen use were included, the positive 13 predictive value increased to 89% and negative predictive value remained at 100%. In contrast to tamoxifen, fulvestrant is a pure ER antagonist, which can down-regulate 21 ER expression in a dose-dependent fashion without any agonistic effects. Therefore FES-PET 22 is a very suitable technique to study the ability of fulvestrant to reduce ER availability and to Previous studies provided FES-PET data for patients treated with tamoxifen (12) ,(10).
1
For example, in a study in 40 patients, after 7-10 days of tamoxifen therapy FES uptake 2 decreased by 55% in patients having clinical benefit compared to 19% in non-responding 3 patients (12) . However, this incomplete reduction in FES uptake should not lead to the 4 conclusion that tamoxifen dosing is suboptimal, as it can take several weeks for tamoxifen to 5 reach steady-state levels.
6
A retrospective study in 11 patients who underwent fulvestrant therapy showed a 7 mean decrease of 49% in FES uptake in tumors (10). This study differed from our current 8 study in several respects. Patients had received lower fulvestrant doses, i.e. 250 mg or 500 9 mg at day 1, followed by 250 mg on day 14, day 28 and every 4 weeks thereafter. Moreover, 10 only one follow-up scan was performed, between 1 and 18 weeks after therapy initiation, and 11 the FES-PET scans were not synchronized with fulvestrant injections. This could have 12 affected the results since plasma fulvestrant levels can vary 10-fold between two doses (15).
13
We therefore performed FES-PET at stringent time points in all patients, concurrent with 14 determination of plasma fulvestrant levels.
15
In our study, like in other FES-PET studies, patients were required to discontinue 16 tamoxifen at least 5 weeks prior to baseline FES-PET to prevent competitive binding (14) .
17
However, the lowest median FES uptake was recorded in the four patients that used 18 tamoxifen until 5 weeks prior to FES-PET. In two of these patients, an earlier FES-PET scan 19 was available while they were still on aromatase inhibitor treatment. These PET scans 20 showed more tumor lesions and a higher median SUV max. It is likely that a generally used 5-21 week stopping period for tamoxifen is too short to reliably measure baseline ER expression 22 by FES-PET. The reported half life for tamoxifen is 4 days, but this can be longer for its 23 metabolites with a half life of even 400 days for N-desmethyltamoxifen (16 The effect of fulvestrant on tumor ER availability could be visualized after only two 8 doses of fulvestrant. In our feasibility study with a small number of patients, a reduction in 9 FES uptake larger than 75% was significantly associated with clinical benefit. Because it 10 takes several months before therapy effects can be reliably measured by anatomical imaging 11 techniques, such as CT scan (17), earlier prediction of treatment response would be valuable.
12
Moreover, ER-positive breast cancer is characterized by bone-dominant disease (18), as was 13 also evident in this study. It is notoriously difficult to evaluate treatment response in bone 14 lesions, and therefore they are considered non-measurable by RECIST v1.1 criteria.
15
Therefore, future studies should address whether serial FES-PET can offer an early response 16 measurement in patients with bone-dominant disease.
17
Our study has some limitations. First, given the character of the study the sample size 18 was relatively modest. Due to progressive disease and treatment withdrawal a third scan was 19 available in only nine patients. In four patients, the second scan was delayed for logistic 20 reasons. However, the scans were still performed on the same pharmacokinetic trough, i.e. We observed that patients with incomplete reduction in FES uptake were more likely FDHT-PET, it may be possible that >90% reduction in FES uptake can be obtained with 20 higher doses of fulvestrant. This may also be clinically feasible. In a randomized phase III 21 study comparing fulvestrant 500 mg to 250 mg, toxicity was equally mild in both groups (5, 22 22). In addition, in a neoadjuvant study in premenopausal patients, a single injection with 23 fulvestrant 750 mg was well tolerated (23) . As an alternative to an increased dose, a higher 24 frequency of administration (e.g. every 2 or 3 weeks) might also be an option. However, our results suggest that not all patients need a higher dose, since fulvestrant reduced ER 1 availability sufficiently in 62% of the patients. Conversely, not all patients with complete 2 reduction in ER availability will experience clinical benefit, since other mechanisms aside 3 from inadequate dosing can be responsible for therapy failure. Among these potential 4 mechanisms are ESR1 mutation and up-regulation of growth factor receptor pathways (24) .
5
The optimal drug dose that leads to complete reduction in ER availability could be 6 verified with FES-PET. This approach would clearly differ from the current approach for 7 endocrine drugs, where the principle 'one-dose-fits-all' is applied, despite the fact that serum 8 and tissue drug levels can vary considerably between patients and at different doses (25) .
9
Some authors have therefore suggested therapeutic drug monitoring and dose escalation 10 based on serum or plasma drug levels (26). In addition, FES-PET could prove useful during 11 drug development, to evaluate the dose required for optimal ER downregulation for new 12 compounds that block or degrade ER. 
METHODS
15
The study was conducted at the University Medical Center Groningen (UMCG), the positive metastatic breast cancer were eligible for the study when they had progressive 1 disease after 2 or 3 lines of palliative hormonal therapy. Other eligibility criteria were ECOG 2 performance ≤ 2, life expectancy > 3 months, and a creatinine clearance > 30 mL/min.
3
Exclusion criteria were previous fulvestrant therapy, the presence of life-threatening visceral 4 metastases, central nervous system metastases, and more than 2 lines of palliative 5 chemotherapy. To prevent competition between FES and drugs from previous therapies, the 6 patients were required to discontinue drugs known to bind ER for at least 5 weeks prior to 
Study Design
10
We performed an imaging trial in patients on salvage endocrine therapy with standard 11 fulvestrant dosing. The patients were imaged just prior to each fulvestrant administration. The 12 aim of this feasibility study was to evaluate the effects of fulvestrant on ER availability. The worsening such that the overall tumor burden, biochemistry (e.g. tumor markers, liver 10 function), and/ or complaints increased sufficiently to merit discontinuation of therapy (27).
11
Final response classification was done by the treating medical oncologist while blinded for Knoxville, TN). FES was produced and administered to the patient as described earlier (14, 
performed at baseline (Scan 1), day 28 ± 2 (Scan 2) and 84 ± 2 (Scan 3). The first and third 1 PET scans were combined with a diagnostic CT scan as part of the staging. FES-PET scan 2 2 was combined with a low-dose CT for attenuation correction. We observed that patients who had used tamoxifen until 5 weeks prior to FES-PET 14 had a very low tumor FES uptake. Therefore, for an explorative analysis, we used an earlier were determined by fluorescent-immuno-assay concurrently with scan 1, scan 2 and scan 3.
5
Since fulvestrant is known to cause cross-reactivity with the estradiol assay, calibration 6 curves were obtained to assess the increase in apparent serum estradiol levels for increasing 7 doses of fulvestrant (Supplementary data, Supplementary Fig. S2 ). This calibration curve was 
Statistical Analysis
13
We aimed to include 15 patients to provide an estimate of the proportion of patients 14 with incomplete reduction in FES tumor uptake defined as described previously (relative 15 decrease < 75% in median lesion SUV cor and absolute median tumor SUV max > 1.5). The authors declare no potential conflicts of interest. Dr. Hospers received a research grant 1 made available to the UMCG from AstraZeneca. 
